Dublin, Dec. 17, 2018 (GLOBE NEWSWIRE) -- The "Chronic Respiratory Disease Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.
Chronic Respiratory Disease Drug Development Pipeline Review, 2018, provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, being overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. There are 275 products in development for this indication.
COPD is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs, leading to shortness of breath and blocked airflow to the lungs. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over time, increasing complications. The main risk factor is smoking. Exposure to chemicals and air pollution also contribute in the development of COPD. There are 187 products in development for this indication.
IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. There are 136 products in development for this indication.
Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Key Topics Covered:
1 Introduction
1.1 Chronic Respiratory Disease Report Coverage
1.2 Asthma - Overview
1.3 Chronic Obstructive Pulmonary Disease (COPD) - Overview
1.4 Idiopathic Pulmonary Fibrosis - Overview
2 Therapeutics Development
2.1 Asthma
2.2 Chronic Obstructive Pulmonary Disease (COPD)
2.3 Idiopathic Pulmonary Fibrosis
3 Therapeutics Assessment
3.1 Asthma
3.2 Chronic Obstructive Pulmonary Disease (COPD)
3.3 Idiopathic Pulmonary Fibrosis
4 Companies Involved in Therapeutics Development
4.1 Asthma
4.2 Chronic Obstructive Pulmonary Disease (COPD)
4.3 Idiopathic Pulmonary Fibrosis
5 Dormant Projects
5.1 Asthma
5.2 Chronic Obstructive Pulmonary Disease (COPD)
5.3 Idiopathic Pulmonary Fibrosis
6 Discontinued Products
6.1 Asthma
6.2 Chronic Obstructive Pulmonary Disease (COPD)
6.3 Idiopathic Pulmonary Fibrosis
7 Product Development Milestones
7.1 Asthma
7.2 Chronic Obstructive Pulmonary Disease (COPD)
7.3 Idiopathic Pulmonary Fibrosis
8 Appendix
Companies Mentioned
- 4D Pharma PLC
- AbbVie Inc
- Accolade Pharmaceuticals LLC
- Ache Laboratorios Farmaceuticos SA
- AdAlta Ltd
- Advanced Inhalation Therapies (AIT) Ltd
- Aeolus Pharmaceuticals Inc
- AlgiPharma AS
- ALK-Abello AS
- Allergan Plc
- Allergopharma GmbH & Co KG
- Allinaire Therapeutics LLC
- Almirall SA
- Amgen Inc
- Amphastar Pharmaceuticals Inc
- Amplia Therapeutics Ltd
- AnaMar AB
- AnaptysBio Inc
- AnGes Inc
- Angiocrine Bioscience Inc
- Antisense Therapeutics Ltd
- Apollo Endosurgery Inc
- Aridis Pharmaceuticals Inc
- Asahi Kasei Corp
- ASIT Biotech SA
- Aslan Pharmaceuticals Pte Ltd
- Aurigene Discovery Technologies Ltd
- AusBio Ltd
- BerGenBio ASA
- Biocon Ltd
- Biogen Inc
- BiosanaPharma BV
- BioStem Technologies Inc
- Biotec Pharmacon ASA
- BreStem Therapeutics Inc
- Bristol-Myers Squibb Co
- C4X Discovery Holdings PLC
- Celdara Medical LLC
- Celgene Corp
- Certa Therapeutics Pty Ltd
- China Resources Pharmaceutical Group Ltd
- Chronic Obstructive Pulmonary Disease (COPD)
- Cipla Ltd
- Circassia Pharmaceuticals Plc
- Compugen Ltd
- Crossject SA
- CrystalGenomics Inc
- CSPC Pharmaceutical Group Limited
- Cumberland Pharmaceuticals Inc
- Daewoong Pharmaceutical Co Ltd
- Denceptor Therapeutics Ltd
- Denovo Biopharma LLC
- Diffusion Pharmaceuticals Inc
- Domainex Ltd
- Energenesis Biomedical Co Ltd
- Errant Gene Therapeutics LLC
- Evaxion Biotech ApS
- FibroGen Inc
- FibroStatin SL
- FLX Bio Inc
- Fountain Biopharma Inc
- Galecto Biotech AB
- Genentech Inc
- GeneScience Pharmaceuticals Co Ltd
- GenKyoTex SA
- Gilead Sciences Inc
- Global Blood Therapeutics Inc
- Gossamer Bio Inc
- Grifols SA
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Humanigen Inc
- Hydra Biosciences Inc
- iBio Inc
- iCo Therapeutics Inc
- Idiopathic Pulmonary Fibrosis
- Idorsia Pharmaceutical Ltd
- InKemia IUCT Group SA
- InMed Pharmaceuticals Inc
- Insmed Inc
- Inspyr Therapeutics Inc
- Inventiva
- Isarna Therapeutics GmbH
- JHL Biotech Inc
- Johnson & Johnson
- Kadmon Corp LLC
- Knopp Biosciences LLC
- Kyorin Pharmaceutical Co Ltd
- Laboratorios LETI SL
- Lead Discovery Center GmbH
- LG Chem Ltd
- LifeMax Laboratories Inc
- Longevity Biotech Inc
- Lung Therapeutics Inc
- Merck & Co Inc
- Mereo Biopharma Group Plc
- Meridigen Biotech Co Ltd
- Miragen Therapeutics Inc
- Mission Therapeutics Ltd
- Mitsubishi Tanabe Pharma Corp
- Moerae Matrix Inc
- Mycenax Biotech Inc
- NAL Pharmaceuticals Ltd
- NeoPharm Co Ltd
- Novo Nordisk AS
- Nuevolution AB
- Nuformix Plc
- Octapharma AG
- OliX Pharmaceuticals Inc
- Omeros Corp
- OncBioMune Pharmaceuticals Inc
- Ono Pharmaceutical Co Ltd
- Onspira Therapeutics Inc
- Orbis Biosciences Inc
- Oxagen Ltd
- Paradigm Biopharmaceuticals Ltd
- Paragen Bio Pty Ltd
- PharmaLundensis AB
- Pieris Pharmaceuticals Inc
- Pliant Therapeutics Inc
- Progenra Inc
- Prommune Inc
- Pulmagen Therapeutics LLP
- Pulmokine Inc
- Pulmotect Inc
- Quark Pharmaceuticals Inc
- Qurient Co Ltd
- Redx Pharma Plc
- Reliance Life Sciences Pvt Ltd
- Resolys Bio Inc
- Revalesio Corp
- ReveraGen BioPharma Inc
- Reviva Pharmaceuticals Inc
- rEVO Biologics Inc
- Rhizen Pharmaceuticals SA
- Sam-A Pharm Co Ltd
- Samumed LLC
- SATT North SAS
- Shionogi & Co Ltd
- Sorrento Therapeutics Inc
- Swecure AB
- Synairgen Plc
- Synermore Biologics Co Ltd
- Synovo GmbH
- Syntrix Biosystems Inc
- Taiho Pharmaceutical Co Ltd
- TaiwanJ Pharmaceuticals Co Ltd
- Telocyte LLC
- Teva Pharmaceutical Industries Ltd
- The Geneva Biotech Center SA
- United BioPharma Inc
- Unizyme Laboratories AS
- Vascular BioSciences
- Vectura Group Plc
- Vicore Pharma AB
- WhanIn Pharmaceutical Co Ltd
- Xencor Inc
- X-Rx Inc
- Yuhan Corp
- Yungjin Pharm Co Ltd
For more information about this report visit https://www.researchandmarkets.com/research/cdkrg4/chronic?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.